Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers
暂无分享,去创建一个
S. Neelakantham | V. Erpenbeck | M. Larbig | D. Sandham | P. Goldsmith | L. Gheyle | E. Vets | W. Elbast | G. Dubois | M. Weiss | Wande Osuntokun